Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10722456 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(13 years from now) | |
US10799517 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(13 years from now) | |
US9949990 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(13 years from now) | |
US9795620 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(13 years from now) | |
US9572819 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(13 years from now) | |
US10376527 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | May 5, 2023 |
Market Authorisation Date: 05 May, 2020
Treatment: Acute treatment of migraine with or without aura in adults
Dosage: SOLUTION;ORAL
11
United States
4
China
3
Australia
2
Brazil
2
Canada
2
India
2
Russia
2
European Union
1
IB
1
Korea, Republic of
1
New Zealand
1
Mexico
1
EA
1
Japan
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic